|
Aug 13
|
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week
|
|
Aug 2
|
Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Aug 1
|
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target
|
|
Jul 31
|
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
|
|
Jul 31
|
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
|
|
Jul 30
|
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval
|
|
Jul 29
|
Repligen (RGEN) Lags Q2 Earnings Estimates
|
|
Jul 28
|
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
|
|
Jul 28
|
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 24
|
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
|
|
Jul 16
|
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
|
|
Jul 15
|
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
|
|
Jul 9
|
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M
|
|
Jul 7
|
High Growth Tech Stocks To Watch In The US July 2025
|
|
Jul 3
|
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing
|
|
Jul 1
|
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
|
|
Jul 1
|
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
|
|
Jun 13
|
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
|
|
Jun 9
|
Sobi and Apellis report new data from Phase III trial for C3G and IC-MPGN
|
|
Apr 23
|
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
|